Data support the potential benefit of a Novel Ex Vivo Cell Modulation Approach to improving Engraftment in patients undergoing Umbilical Cord Blood Transplantation Read more…
Secures US Patent to Novel Small Molecule Modulator of Pluripotent Stem Cells Read more…
Fate Therapeutics’ (San Diego-based developer of stem cell therapies) CEO Paul Grayson is leaving. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.